
EquitySector - HealthcareVery High Risk
Direct
NAV (09-Jun-26)
Returns (Since Inception)
Fund Size
₹85 Cr
Expense Ratio
1.13%
ISIN
INF397L01LK4
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+8.85%
+10.02% (Cat Avg.)
3 Years
+23.73%
+23.58% (Cat Avg.)
5 Years
+12.03%
+13.40% (Cat Avg.)
Since Inception
+18.34%
— (Cat Avg.)
| Equity | ₹78.54 Cr | 92.92% |
| Others | ₹5.98 Cr | 7.08% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹9.43 Cr | 10.61% |
| Divi's Laboratories Ltd | Equity | ₹6.72 Cr | 7.56% |
| Treps | Cash - Repurchase Agreement | ₹6.49 Cr | 7.29% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹5.9 Cr | 6.63% |
| Torrent Pharmaceuticals Ltd | Equity | ₹5.79 Cr | 6.51% |
| Neuland Laboratories Ltd | Equity | ₹4.89 Cr | 5.49% |
| Navin Fluorine International Ltd | Equity | ₹4.79 Cr | 5.38% |
| Aurobindo Pharma Ltd | Equity | ₹4.43 Cr | 4.98% |
| Fortis Healthcare Ltd | Equity | ₹4 Cr | 4.49% |
| Gland Pharma Ltd | Equity | ₹3.16 Cr | 3.55% |
| Zydus Lifesciences Ltd | Equity | ₹2.8 Cr | 3.15% |
| OneSource Specialty Pharma Ltd | Equity | ₹2.74 Cr | 3.08% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹2.73 Cr | 3.07% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.73 Cr | 3.07% |
| Biocon Ltd | Equity | ₹2.72 Cr | 3.06% |
| Global Health Ltd | Equity | ₹2.65 Cr | 2.97% |
| Metropolis Healthcare Ltd | Equity | ₹2.63 Cr | 2.95% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹2.56 Cr | 2.87% |
| Ipca Laboratories Ltd | Equity | ₹2.53 Cr | 2.85% |
| Mankind Pharma Ltd | Equity | ₹2.04 Cr | 2.29% |
| Acutaas Chemicals Ltd | Equity | ₹1.97 Cr | 2.22% |
| Anthem Biosciences Ltd | Equity | ₹1.93 Cr | 2.16% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹1.92 Cr | 2.15% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.62 Cr | 1.82% |
| Net Receivables / (Payables) | Cash - Collateral | ₹-0.19 Cr | 0.21% |
Large Cap Stocks
33.13%
Mid Cap Stocks
29.02%
Small Cap Stocks
30.77%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹75.9 Cr | 85.32% |
| Basic Materials | ₹6.76 Cr | 7.60% |
Standard Deviation
This fund
16.35%
Cat. avg.
16.65%
Lower the better
Sharpe Ratio
This fund
1.03
Cat. avg.
1.03
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.84
Higher the better
Since April 2026
ISIN INF397L01LK4 | Expense Ratio 1.13% | Exit Load 1.00% | Fund Size ₹85 Cr | Age 7 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹48,681 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments